Making hepatitis E a vaccine-preventable disease

New England Journal of Medicine

Volumn 372, Issue 10, 2015, Pages 899-901

  Teshale, Eyasu ^a   Ward, John W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS E ANTIBODY; HEPATITIS E VACCINE; VIRUS RNA; HEPATITIS VACCINE;

ANTIBODY DETECTION; CLINICAL EFFECTIVENESS; DATA ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; VACCINATION; VACCINE PRODUCTION; VIRUS IDENTIFICATION; FEMALE; IMMUNOLOGY; MALE;

FEMALE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; MALE; VIRAL HEPATITIS VACCINES;

EID: 84924455182     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1415240     Document Type: Article

References (5)

1. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010;376: 895-902.
2. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012;55: 988-97.
3. Gurley ES, Halder AK, Streatfield PK, et al. Estimating the burden of maternal and neonatal deaths associated with jaundice in Bangladesh: possible role of hepatitis E infection. Am J Public Health 2012;102: 2248-54.
4. Drobeniuc J, Greene-Montfort T, Le NT, et al. Laboratory-based surveillance for hepatitis E virus infection, United States, 2005- 2012. Emerg Infect Dis 2013;19: 218-22.
5. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007;356: 895-903.